Business Wire

Global Foundation Launches to Accelerate an End to Smoking

Del

With the goal of eliminating smoking worldwide, the Foundation for a Smoke-Free World formally launched today in New York City. The Foundation is founded and led by Dr. Derek Yach, a renowned anti-smoking crusader who, while at the World Health Organization (WHO), was the primary architect of the WHO’s Framework Convention on Tobacco Control. The Foundation will build upon recent shifts in policy and science to fund research and support collaborative initiatives to accelerate progress in reducing harm and deaths from smoking worldwide.

“For decades, despite significant tobacco control initiatives, smoking has remained the world’s number one preventable cause of death. With more than one billion smokers, and one death every six seconds from smoking, there is an urgent need to accelerate progress and end this public health crisis,” said Dr. Yach, the Foundation’s founder and president-designate. “The Foundation for a Smoke-Free World will bring needed resources, expertise, fresh thinking, and a collaborative spirit to form partnerships, initiate dialogue, conduct research, and take actions to more rapidly rid the world of smoking and its negative health impacts.”

The Foundation has secured initial funding of approximately US$80 million annually over the next 12 years, beginning in 2018, from Philip Morris International (PMI). The Foundation is seeking and expects to receive funding from other sources as well. Importantly, the grant terms, bylaws, and non-profit status of the Foundation preclude PMI or other tobacco industry representatives from involvement in Foundation governance, or from having any influence over the Foundation’s funding decisions, strategy, or activities. The Foundation will have an independent research agenda, ownership of its data, freedom to publish, and strict protections against conflict of interest.

The Foundation’s ongoing activities and research priorities will be informed through a transparent public dialogue, and will be subject to the approval of an independent board of directors. Initial activities are expected to be focused in four areas of need:

  1. Support research into smoking harm reduction and build research capacity through academic centers of excellence
  2. Collaboratively build consensus around which interventions can best reduce harm and deaths from smoking and increase smoking cessation
  3. Measure and report on global progress towards smoking harm reduction
  4. Identify alternative crops and livelihoods for tobacco farmers as the global demand for tobacco declines

“The world needs to act with greater urgency and more creativity to cut the adult smoking rate and prevent cancer, heart disease and lung diseases,” said Dr. John Seffrin, professor of practice at Indiana University-Bloomington School of Public Health and past president of the Union for International Cancer Control. “The Foundation for a Smoke-Free World will bring new energy, needed resources and significant expertise to the fight. The Foundation will fund critical research to help eliminate gaps in science, and help the global community pick up the pace of progress in providing science-based solutions for the world’s one billion smokers, most of whom seek to quit cigarettes.”

The Foundation will also focus its efforts on understanding and helping to address disproportionate challenges and impacts associated with efforts to end smoking in developing countries. For example, the Foundation will work to help smallholder tobacco farmers shift to alternative crops.

“A decline in tobacco production creates an opportunity to solve food insecurity issues that exist in many parts of the world,” said Dyborn Chibonga, CEO of the National Smallholder Farmers’ Association of Malawi. “I look forward to helping the Foundation partner with public and private entities to develop practical solutions to these pressing problems.”

“It is time for new thinking and open, collaborative approaches that speed us closer to our shared goal,” said Dr. Yach. “We’ll need a multitude of approaches – encompassing behavioral and biological science, economics, policy, technology, pharmacology, epidemiology, and agricultural expertise – to develop the right approaches for different regions and cultures. If we work together, I’m confident we can end smoking throughout the world.”

For more information about the Foundation and its activities, or to review its bylaws and certificate of incorporation, please visit www.smoke-freeworld.org.

Editor’s note: Dr. Yach will formally announce the Foundation and outline its goals at 9:30 am EDT today, September 13, during a speech to the Global Tobacco & Nicotine Forum 2017 at the InterContinental New York Barclay in New York City. Dr. Yach will be preceded by Mitch Zeller, director of the US FDA's Center for Tobacco Products, who will speak at 8:45 am EDT about the need for a new approach to smoking cessation. Members of the media are invited to attend.

About the Foundation for a Smoke-Free World

The Foundation for a Smoke-Free World is an independent, non-profit organization dedicated to accelerating global efforts to reduce deaths and harm from smoking, with the ultimate goal of eliminating smoking worldwide. The Foundation also supports populations who are disproportionately burdened by a rapid transition away from smoking, with an initial focus on helping tobacco farmers in the developing world. For more information about the Foundation, please visit www.smoke-freeworld.org.

Contact information

for The Foundation for a Smoke-Free World
Tom Langford, 617-761-6775
tom.langford@fkhealth.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31Pressemelding

Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00Pressemelding

AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20Pressemelding

AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute

Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11Pressemelding

The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other

Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20Pressemelding

Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to

Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31Pressemelding

Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom